NBDF/ LinkedIn
Aug 31, 2025, 07:31
Avatrombopag Shows Promise for Pediatric Immune Thrombocytopenia in Late-Stage Global Trial: NBDF
National Bleeding Disorders Foundation shared on LinkedIn:
“Promising news for children and adolescents living with immune thrombocytopenia (ITP). A late-stage global trial shows avatrombopag, an oral treatment already approved for adults, can significantly improve platelet counts and reduce bleeding symptoms in pediatric patients, offering a potential new treatment option for an underserved population.
Learn more about the study results and what they could mean for pediatric ITP care in The Lancet Haematology.”
Stay updated with Hemostasis Today.
-
Apr 27, 2026, 07:08Jeff Schaffnit: Global Voices in Hemophilia Care at the World Federation of Hemophilia World Congress
-
Apr 27, 2026, 06:44Andrew M. Evens: Award-Winning Research from the British Society for Haematology 66th Annual Meeting
-
Apr 27, 2026, 05:19Harshal Kale: Celebrating Hemophilia Partnerships on a Global Stage
-
Apr 26, 2026, 17:17Ajigbotosho Barakat: Leg Strength as a Key to Healthy Aging
-
Apr 26, 2026, 17:02Francisco Chacón-Lozsán: Limited Evidence Methylene Blue in Vasoplegic Shock
-
Apr 26, 2026, 16:57Gopal Patidar: Key Areas of Haemovigilance in ISBT Transfusion Today
-
Apr 26, 2026, 16:56Cathy Harrison: Oral Health in Older Adults Assessing the Impact of Ageing, Heart Failure, and Social Isolation
-
Apr 26, 2026, 15:08Andreas Ejlegård: Rebalancing Thrombosis and Hemostasis Through Mechanistic Innovation
-
Apr 26, 2026, 14:55Vanessa Simioni Faria: Precision Anticoagulation and Expanding Donor Frontiers